摘要
目的探讨131I标记抗CEA单抗在裸鼠人结肠癌肝转移模型的体内分布及其抑制肝转移的作用。方法在建立裸鼠人结肠腺癌肝转移模型的基础上 ,用131I标记抗CEA单抗COL 1 ,注射荷瘤裸鼠 ,观察 131I标记抗CEA单抗在荷瘤裸鼠体内分布及抑制肝转移的作用。结果体外标记抗体特异性结合率为59.9 %。在注射131I标记COL 1后24～96h肝转移灶内均有特异性放射性浓聚 ,96h瘤/肝比值为4.21。给予非特异性的131I NMIgG后 ,肝转移灶未见放射性浓聚 ,而呈全身均匀分布。131 Ⅰ COL 1治疗后3周 ,肝转移灶内癌组织可见大片坏死 ,血清CEA水平显著下降 ,肝转移灶数目及大小的抑制率分别为36.8 %和41.7%。结论131I 抗CEA单抗对防治结肠癌肝转移有潜在的临床应用前景。
Objective To study the distribution of 131I-labeled anti-CEA monoclonal antibody and its therapeutic effect on the hepatic metastatic foci of human colonic cancer in nude mice. Methods The nude mouse model of human colonic cancer with hepatic metastasis was established. 131I-labeled anti-CEA monoclonal antibodies were injected into the mice. Then, the distribution of the monoclonal antibodies was determined and the feasibility of radioimmuno-therapy for the hepatic metastatic foci of human colonic cancer was observed. Results The specific binding rate of the monoclonal antibodies to the cells of colonic cancer in vitro was 59.9%. The radioactivity in the hepatic metastatic foci was measured with a gamma counter 24 to 96 hours after the injection of the anti-CEA monoclonal antibodies. The cancer/liver distribution ratio was 4.21 96 hours after injection while an injection of 131I-NMIgG resulted in an even distribution over the whole body. 3 weeks after injection, more significant inhibition on the number and diameter of the hepatic metastatic foci was observed in the treated mice as compared with the control (P<0.05). Serum CEA level was lower in the treated mice, too. Histological examination revealed that there were large necrotic areas in the cancerous foci concentrated with the monoclonal antibodies. Conclusion 131I-labeled anti-CEA monoclonal antibodies can be used in radioimmunotherapy for the hepatic metastatic foci of colorectal cancer.
出处
《第三军医大学学报》
CSCD
北大核心
2000年第4期360-362,共3页
Journal of Third Military Medical University
关键词
单克隆抗体
^131I-CEA
结肠癌
肝转移
s:monoclonal antibody
radioimmunotherapy
metastasis
colonic cancer
nude mouse
